NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Many people, hedge funds and others, in my opinion, don’t understand that it’s looking like NWBO is creating a true class of long term GBM survivors by treating them with DCVax-l, whereas in the past, most long term survivors getting SOC therapy were, by today’s standards, not suffering from GBM, but were instead exhibiting idh mutations — which are no longer considered GBM by the World Health Organization.

I also don’t think these same people/institutions realize how rare idh mutations are in other cancers. For instance:

A total of 12,372 patients from more than 20 solid tumor species were analyzed, including biliary carcinoma (960 cases), liver cancer (1433 cases), lung cancer (3557 cases) and colorectal cancer (1310 cases).

(Only) 105 cases (0.8%) with IDH mutations were identified. — 2020 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13638

Conclusion? There is a reason NWBO is preparing manufacturing readiness and ramp capacity for a demanding future.